Patient information about HPV and the HPV vaccine

van Zyl, Tavé; Wooltorton, Eric; MacDonald, Noni
August 2007
CMAJ: Canadian Medical Association Journal;8/28/2007, Vol. 177 Issue 5, p462
Academic Journal
Question & Answer
The article presents questions and answers related to patient information about human papillomavirus (HPV) and the HPV vaccine including how is HPV transmitted, the signs and symptoms of genital HPV infection, and is the HPV vaccine safe.


Related Articles

  • Human Papilloma Virus Vaccines and Current Controversy. Choudhury, Panna; Yewale, Vijay // Indian Pediatrics;Mar2011, Vol. 48 Issue 3, p248 

    The article discusses a reply to the letter regarding the current controversies on using human papilloma virus (HPV) vaccines in India. It states that the study used commercially available HPV vaccines in India with approval from the Drug Controller General of India (DCGI), European Medicines...

  • Analysis of Risk-Structured Vaccination Model for the Dynamics of Oncogenic and Warts-Causing HPV Types. Alsaleh, Aliya; Gumel, Abba // Bulletin of Mathematical Biology;Jul2014, Vol. 76 Issue 7, p1670 

    A new deterministic model is designed and used to assess the community-wide impact of mass vaccination of new sexually active individuals on the dynamics of the oncogenic and warts-causing HPV types. Rigorous qualitative analyses of the model, which incorporates the two currently available...

  • Genitourinary Conditions. Carnes, Molly; Mahoney, Jane E. // Annals of Internal Medicine;4/6/2004, Vol. 140 Issue 7, p538 

    Focuses on the reduction in the incidence of both HPV-16 Infection and HPV-16-related Cervical Intraepithelial Neoplasia by Human papillomavirus (HPV) type 16 vaccine. Effects of Human papillomavirus (HPV) infection; Need for confirming the long-term efficacy and safety of the vaccine in future...

  • Human Papilloma Virus Vaccine Introduction and Framework for Impact Evaluation.  // Immunization Newsletter;Aug2013, Vol. 35 Issue 4, p7 

    The article presents information on vaccines developed by countries in Latin America and the Caribbean against human papillomavirus (HPV) under their national immunization programs. In July 2013, ten countries have included the HPV vaccine in their immunization schedules, with 4.5 million girls...

  • The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety. Fonteneau, Laure; Ragot, Marine; du Châtelet, Isabelle Parent; Guthmann, Jean-Paul; Lévy-Bruhl, Daniel; Parent du Châtelet, Isabelle // BMC Public Health;12/12/2015, Vol. 15 Issue 1, p1 

    Background: Since 2011 public concerns about Human Papillomavirus (HPV) vaccination safety and efficacy arose in France. We explored the relevance of using vaccines reimbursement data to assess the impact of those public concerns on vaccination coverage.Methods: We used...

  • Ethical considerations of universal vaccination against human papilloma virus. Navarro-Illana, Pedro; Aznar, Justo; Díez-Domingo, Javier // BMC Medical Ethics;2014, Vol. 15 Issue 1, p1 

    Background From an epidemiological perspective, the practice of universal vaccination of girls and young women in order to prevent human papilloma virus (HPV) infection and potential development of cervical cancer is widely accepted even though it may lead to the neglect of other preventive...

  • Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Soybilgic, Arzu; Onel, Karen B.; Utset, Tammy; Alexander, Kenneth; Wagner-Weiner, Linda // Pediatric Rheumatology;2013, Vol. 11 Issue 1, p1 

    Background: Women with SLE have higher rates of persistent human papilloma virus (HPV) infections and precancerous lesions than healthy women. HPV vaccine is safe and effective in healthy females aged 9-26 years. There are limited data on the safety and immunogenicity of HPV vaccine in females...

  • Parental attitudes and information needs in an adolescent HPV vaccination programme. Stretch, R.; Roberts, S. A.; McCann, R.; Baxter, D.; Chambers, G.; Kitchener, H.; Brabin, L. // British Journal of Cancer;12/2/2008, Vol. 99 Issue 11, p1908 

    We sent a questionnaire to 38% (1084) of 2817 parents whose daughters had been offered human papillomavirus vaccination and who had agreed to participate. Of these, 60% (651) returned a questionnaire. Responses suggested that fact sheets and parent information evenings confirmed, rather than...

  • Understanding Public Perceptions of the HPV Vaccination Based on Online Comments to Canadian News Articles. Feinberg, Yael; Pereira, Jennifer A.; Quach, Susan; Kwong, Jeffrey C.; Crowcroft, Natasha S.; Wilson, Sarah E.; Guay, Maryse; Lei, Yang; Deeks, Shelley L.; null, null // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Background: Given the variation in human papillomavirus (HPV) vaccine coverage across Canada, and debate regarding delivery of HPV vaccines in Catholic schools, we studied online comments on Canadian news websites to understand public perceptions of HPV and HPV vaccine. Methods: We searched...

  • Update: Vaccines for Women, Adolescence through Adulthood. Akinsanya-Beysolow, Iyabode; Wolfe, Charles // Journal of Women's Health (15409996);Aug2009, Vol. 18 Issue 8, p1101 

    Recommendations for routine vaccination of adolescents and adults are continually evolving; new vaccines are licensed, and ongoing studies lead to updated recommendations for existing vaccines. Although vaccination is important for both sexes, some recent developments are particularly relevant...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics